1 unread notifications
David Schenkein leads GV’s life sciences investment team as a general partner, drawing on a career as a hematologist, oncologist, and drug developer. David previously spent ten years as CEO of Agios Pharmaceuticals and led clinical development work at Genentech and Millennium Pharmaceuticals, including work on the cancer treatment Velcade.
David Schenkein leads GV’s life sciences investment team as a general partner, drawing on a career as a hematologist, oncologist, and drug developer. David previously spent ten years as CEO of Agios Pharmaceuticals and led clinical development work at Genentech and Millennium Pharmaceuticals, including work on the cancer treatment Velcade.
Career
General Partner at GV until Present